← Back to Screener
Silence Therapeutics Plc American Depository Share (SLN)
Price$6.53
Value ScoreF
Growth ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-36.42%
Price vs S&P 500 (4W)-38.38%
VGM Score26.71
Market Capitalization$324.03M
All Metrics
Book Value / Share (Quarterly)$0.44
P/TBV (Annual)26.24x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)315.49%
Price vs S&P 500 (YTD)-50.14%
Gross Margin (TTM)79.50%
Net Profit Margin (TTM)-8943.86%
EPS (TTM)$-0.53
10-Day Avg Trading Volume0.00M
EPS Excl Extra (TTM)$-0.53
Revenue Growth (5Y)305.31%
ROI (Annual)-48.53%
Gross Margin (Annual)37.83%
Net Profit Margin (5Y Avg)-422.12%
Cash / Share (Quarterly)$0.08
Revenue Growth QoQ (YoY)-99.92%
ROA (Last FY)-39.75%
Revenue Growth TTM (YoY)-99.27%
EBITD / Share (TTM)$-0.54
ROE (5Y Avg)-135.82%
Operating Margin (TTM)-9345.05%
Cash Flow / Share (Annual)$-0.52
P/B Ratio5.20x
P/B Ratio (Quarterly)4.66x
Net Income / Employee (Annual)$-490,657,800,000
EV / Revenue (TTM)750.01x
Net Interest Coverage (TTM)-15.11x
ROA (TTM)-56.37%
EPS Incl Extra (Annual)$-0.53
Current Ratio (Annual)4.46x
Quick Ratio (Quarterly)8.06x
3-Month Avg Trading Volume0.00M
52-Week Price Return-72.00%
Revenue / Employee (TTM)$9,500
Tangible BV / Share (Quarterly)$0.44
P/S Ratio (Annual)20.61x
Asset Turnover (Annual)0.17x
52-Week High$2.63
Operating Margin (5Y Avg)-486.99%
EPS Excl Extra (Annual)$-0.53
CapEx CAGR (5Y)149.02%
Tangible BV CAGR (5Y)-20.87%
26-Week Price Return-31.07%
13-Week Price Return7.05%
Total Debt / Equity (Annual)2.02x
Current Ratio (Quarterly)8.72x
Enterprise Value$312.75M
Revenue / Share Growth (5Y)279.98%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-22.83%
Revenue / Employee (Annual)$212,082,300,000
Pretax Margin (Annual)-270.66%
Cash / Share (Annual)$0.83
Net Income / Employee (TTM)$-852,700
ROE (Last FY)-264.65%
Net Interest Coverage (Annual)-6.60x
EPS Basic Excl Extra (Annual)$-0.53
Receivables Turnover (TTM)0.86x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.53
Receivables Turnover (Annual)28.09x
ROI (TTM)-103.26%
P/S Ratio (TTM)386.21x
Pretax Margin (5Y Avg)-484.47%
Revenue / Share (Annual)$0.23
Tangible BV / Share (Annual)$0.16
Price vs S&P 500 (52W)-75.27%
Year-to-Date Return-47.00%
5-Day Price Return-55.83%
EPS Normalized (Annual)$-0.53
ROA (5Y Avg)-43.18%
Net Profit Margin (Annual)-231.35%
Month-to-Date Return-55.08%
Cash Flow / Share (TTM)$-0.33
Operating Margin (Annual)-277.66%
LT Debt / Equity (Annual)1.19x
ROI (5Y Avg)-53.35%
LT Debt / Equity (Quarterly)0.57x
EPS Basic Excl Extra (TTM)$-0.53
P/TBV (Quarterly)4.68x
P/B Ratio (Annual)3.53x
Pretax Margin (TTM)-8942.55%
Book Value / Share (Annual)$0.26
Price vs S&P 500 (13W)3.44%
Beta2.63x
Revenue / Share (TTM)$0.01
ROE (TTM)-103.26%
52-Week Low$1.06
vGradeF
gGradeD
mGradeD
vgmGradeD
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SLNSilence Therapeutics Plc American Depository Share | F | D | D | $6.53 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Silence Therapeutics is a biotechnology company developing short-interfering RNA (siRNA) therapeutics using its proprietary mRNAi GOLD platform. The company's pipeline targets cardiovascular disease, hematology, and rare diseases, with lead candidates Divesiran for hematological disorders and Zerlasiran for cardiovascular conditions. Silence also generates revenue through out-licensed programs with third-party collaborators.